Extended Data Fig. 9: T cell response in both naïve and tumour-bearing immunocompetent mice treated with RMC-7977.
From: Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
a,b, C57BL/6 J mice were vaccinated with 1×106 OVA peptide (SIINFEKL)-pulsed BMDCs on day 0 and day 8. Mice were treated with 25 mg/kg RMC-7977 or vehicle PO daily starting one day before vaccination (day −1). Mice were euthanized on day 15 after treatment start, and spleens were harvested and assessed for frequency of antigen specific (H-2Kb SIINFEKL tetramer positive) CD8 + T cells by flow cytometry (a) and for IFNγ production by ELISpot. Quantification shown in (b). Each bar represents mean ±s.e.m; each dot represents an individual mouse. n = 3-4 mice/group; ns=not significant (unpaired two-sided Student’s t test). c,d,e, Levels of immune cells, CD8 + T cells, and tumour antigen (AH1) specific CD8 + T cells in murine colon carcinoma CT26 syngeneic tumours, engineered to express KRASG12C, at 24 h post 4 days of treatment with RMC-7977 at 25 mg/kg PO QD shown as percentage of Live (c), CD45+ (d), and CD8+ cells (e), n = 4 mice per group, bars represent mean ± s.e.m, * p = 0.0286; ** p = 0.0079; **** p = 0.000006 by unpaired two-sided Student’s t test.